… oxaliplatin dosing in cancer patients with hepatic impairment, we initiated this dose-escalating, …
of single-agent oxaliplatin in patients with hepatic dysfunction as defined by the following …

… oxaliplatin dosing guidelines in renally impaired patients have … Therefore, we initiated this
dose-escalating pharmacokinetic … Dose-escalating and pharmacological study of oxaliplatin in …

… in oxaliplatin elimination, we conducted a dose-escalating … Institute's Organ Dysfunction
Working Group. In this … in each organ dysfunction group, except for group A where at least 12 …

… bile, and as such patients with impaired hepatic function were … dosing in patients with cancer
with hepatic dysfunction was … for pharmacologic analysis.) during the conduct of the study. …

… anatomic resection with preservation of liver function impossible. Additional eligibility criteria
… of colorectal metastases confined to the liver: a clinical and pharmacologic evaluation. Eur J …

… of liver function in patients with different cancers. The severity of … the organ dysfunction,
pharmacokinetics and pharmacology … such as the NCI Organ Dysfunction Working Group (NCI-…

… allowed many mCRC patients to be … study, the rate conversion surgery to patients with
oxaliplatin-based chemotherapy was about 40%. Even in patients with impaired renal function (Ccr…

… Patients were assigned to four hepatic function groups … the National Cancer Institute Organ
Dysfunction Working Group … to treatment in a patient in the mild hepatic impairment group …

… Organ Dysfunction Working Group's hepatic impairment categorization and two drug-induced
liver … scores of hepatic function, such as the Model for End-Stage Liver Disease or Child–…

… Hepatic dysfunction was categorized as mild, moderate, or severe by the National Cancer
Institute Organ Dysfunction Working Group criteria. Fifteen patients with normal liver function …